A fully lab-grown solid organ is successfully transplanted into a human patient in a clinical trial before 203

Question

Six frontier AI models put this at 18% by 17 Sept 2036. Full reasoning from every model.

WillHappen.ai · Accepted Answer

18% — the median of 6 frontier models, resolving by 2036-09-17.

Answer

Gemini (Google): 27% — Success hinges on solving microvascular perfusion and immune longevity in complex 3D tissue architecture before FDA human trial clearance. Simple bioengineered tissues like bladders and skin exist, but vascularizing thick solid organs remains unsolved at scale. FDA IND clearance requires years of sustained large-animal survival, which current preclinical bioprinted organs have not achieved. A 2032 deadline leaves under six years, meaning Phase 1 human recruitment would need to begin by 2029 to record successful outcomes.

Answer

Claude (Anthropic): 10% — Turns on whether bioprinted/scaffold-grown solid organs (kidney, liver) reach human implantation, not just decellularized/partial constructs. Current progress is limited to bladder, trachea patches, and small vascularized tissue constructs, not full solid organs like kidney or liver. Regulatory pathways for a fully lab-grown solid organ require years of animal validation before any human trial, and none are near that stage as of 2026. A breakthrough in vascularization and immune-compatible bioprinting at scale would most change this, but no such leap is currently near clinical translation.

Answer

GPT (OpenAI): 37% — This hinges on whether vascularized, clinically durable organs clear preclinical safety and manufacturing barriers this decade. A sponsor must finish large-animal durability work, win FDA/EMA clearance, and enroll a first-in-human trial before 2032. The field has implanted engineered bladders and grafts, but no fully lab-grown kidney, liver, heart, or lung has yet shown durable human function. A validated long-term primate result for a vascularized kidney or liver by 2029 would materially raise the odds.

Answer

Grok (xAI): 18% — Needs a vascularized, functional solid organ (kidney/liver/heart) cleared for first-in-human trial by ~2030. No group has yet shown a fully lab-grown solid organ surviving long-term in large animals; that bar must be cleared first. IND-to-first-patient typically takes 18–30 months after GLP large-animal data, leaving little calendar room before 2032. Xenotransplantation and simpler constructs (bladder, trachea) set a higher bar than historical tissue-engineering timelines, so this sits well below the 30–40 % base for…

Answer

DeepSeek (DeepSeek): 18% — This hinges on whether any engineered solid organ clears regulators into human trials and shows function within roughly nine years. Only a handful of groups (Tengion, United Therapeutics, IVIVA, Miromatrix) have reached human testing, and mostly with thin or tubular structures, not solid organs. Solid organs need vasculature, billions of cells, and immune tolerance; kidney and liver scaffolds remain at animal or early safety stages as of 2026. The 2036 deadline gives ~10 years, but FDA pathways for a first-in-human engineered organ typically take 5-8 years after preclinical proof, which is not yet in hand.

Answer

Qwen (Alibaba): 4% — No lab-grown solid organ has cleared even Phase I safety trials as of 2026; the vascularization problem remains unsolved. The most advanced programs (e.g., United Therapeutics' pig-to-human xenotransplants, bioprinted skin/cartilage) are not lab-grown solid organs; true de novo organ… Vascularizing a thick tissue construct at clinical scale has no demonstrated solution; even the best 3D-bioprinting groups (e.g., Prellis, Organovo pivoted away) have… A Phase I trial would need FDA IND approval, which requires GLP animal data showing months of function—no group is close to filing; a surprise breakthrough in…

A fully lab-grown solid organ is successfully transplanted into a human patient in a clinical trial before 2032.

What each one said

A fully lab-grown solid organ is successfully transplanted into a human patient in a clinical trial before 2032.

The US FDA approves an anti-aging therapeutic indicated specifically to slow biological aging before 2035.

The US FDA approves a gene therapy targeting sensorineural hearing loss before 2030.

A gene editing therapy for herpes simplex virus enters Phase 3 clinical trials before 2029.

The US FDA approves an in vivo CRISPR gene editing therapy before January 1, 2028.